The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Pfizer
Approval Status: Approved October 1999
Treatment for: For the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter.
General Information
Tikosyn (dofetilide) Capsules for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation /atrial flutter of greater than one week duration who have been converted to normal sinus rhythm.
Tikosyn is also indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus
rhythm. Tikosyn has not been shown to be effective in patients with paroxysmal atrial fibrillation.
Side Effects
Because Tikosyn can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation /atrial flutter is highly symptomatic.
Mechanism of Action
Capsules of dofetilide. Approved interim dissolution method, medium, and specification to be: USP Apparatus I (basket) at 100 rpm in 0.001 M hydrochloric acid; Q=[----] at 30 minutes.
Additional Information
Because Tikosyn can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation /atrial flutter is highly symptomatic.
